These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 9564569)

  • 21. Assessment of antifungal resistance and associated molecular mechanism in Candida albicans isolates from different cohorts of patients in North Indian state of Haryana.
    Kumar A; Nair R; Kumar M; Banerjee A; Chakrabarti A; Rudramurthy SM; Bagga R; Gaur NA; Mondal AK; Prasad R
    Folia Microbiol (Praha); 2020 Aug; 65(4):747-754. PubMed ID: 32219719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A chemical screen identifies structurally diverse metal chelators with activity against the fungal pathogen
    Fallah S; Duncan D; Reichl KD; Smith MJ; Wang W; Porco JA; Brown LE; Whitesell L; Robbins N; Cowen LE
    Microbiol Spectr; 2024 Apr; 12(4):e0409523. PubMed ID: 38376363
    [No Abstract]   [Full Text] [Related]  

  • 23. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.
    Franz R; Kelly SL; Lamb DC; Kelly DE; Ruhnke M; Morschhäuser J
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3065-72. PubMed ID: 9835492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
    Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
    J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifungal drug resistance in Candida: a special emphasis on amphotericin B.
    Ahmady L; Gothwal M; Mukkoli MM; Bari VK
    APMIS; 2024 May; 132(5):291-316. PubMed ID: 38465406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans.
    Heilmann CJ; Schneider S; Barker KS; Rogers PD; Morschhäuser J
    Antimicrob Agents Chemother; 2010 Jan; 54(1):353-9. PubMed ID: 19884367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting efflux pumps to overcome antifungal drug resistance.
    Holmes AR; Cardno TS; Strouse JJ; Ivnitski-Steele I; Keniya MV; Lackovic K; Monk BC; Sklar LA; Cannon RD
    Future Med Chem; 2016 Aug; 8(12):1485-501. PubMed ID: 27463566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans.
    Alarco AM; Raymond M
    J Bacteriol; 1999 Feb; 181(3):700-8. PubMed ID: 9922230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.
    Madaan K; Bari VK
    Microb Drug Resist; 2023 Aug; 29(8):319-332. PubMed ID: 37327022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.
    Ruhnke M; Adler A; Müller FM
    Clin Microbiol Infect; 2000 Apr; 6(4):220-3. PubMed ID: 11168112
    [No Abstract]   [Full Text] [Related]  

  • 31. Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
    Ambati S; Ellis EC; Lin J; Lin X; Lewis ZA; Meagher RB
    mSphere; 2019 Oct; 4(5):. PubMed ID: 31666315
    [No Abstract]   [Full Text] [Related]  

  • 32. The
    Mahdizade AH; Hoseinnejad A; Ghazanfari M; Boozhmehrani MJ; Bahreiny SS; Abastabar M; Galbo R; Giuffrè L; Haghani I; Romeo O
    Microb Drug Resist; 2024 Jul; 30(7):288-296. PubMed ID: 38770776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Evolution of Antifungal Drug Resistance.
    Robbins N; Caplan T; Cowen LE
    Annu Rev Microbiol; 2017 Sep; 71():753-775. PubMed ID: 28886681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.
    Martínez M; López-Ribot JL; Kirkpatrick WR; Bachmann SP; Perea S; Ruesga MT; Patterson TF
    J Antimicrob Chemother; 2002 Mar; 49(3):515-24. PubMed ID: 11864952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetics of medically important fungi.
    Whelan WL
    Crit Rev Microbiol; 1987; 14(2):99-170. PubMed ID: 3549159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
    Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
    J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fungal resistance.
    Bernhardt H; Zimmermann K; Knoke M
    Infection; 1999; 27 Suppl 2():S52-4. PubMed ID: 10885830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes.
    MacPherson S; Akache B; Weber S; De Deken X; Raymond M; Turcotte B
    Antimicrob Agents Chemother; 2005 May; 49(5):1745-52. PubMed ID: 15855491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.
    White TC; Pfaller MA; Rinaldi MG; Smith J; Redding SW
    Oral Dis; 1997 May; 3 Suppl 1():S102-9. PubMed ID: 9456667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.
    Perlin DS
    Drugs; 2014 Sep; 74(14):1573-85. PubMed ID: 25255923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.